If I have another minute or two, Mr. Chair, I'm particularly concerned in regard to patients accessing new therapies. In consideration of the investment we made in research, and you and other guests have referenced it before, are Canadians with diabetes not benefiting from new therapies because of CDR or other mechanisms?
On May 2nd, 2007. See this statement in context.